E
Evangelos Terpos
Researcher at National and Kapodistrian University of Athens
Publications - 858
Citations - 33515
Evangelos Terpos is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 73, co-authored 725 publications receiving 25857 citations. Previous affiliations of Evangelos Terpos include Hammersmith Hospital & Imperial College London.
Papers
More filters
Journal ArticleDOI
Clinical Characteristics and Outcomes of Oligosecretory and Non-Secretory Multiple Myeloma
Magdalini Migkou,Yael C Cohen,Efstathios Kastritis,Maria Gavriatopoulou,Evangelos Eleutherakis-Papaiakovou,Despoina Fotiou,Maria Roussou,Dimitrios C. Ziogas,Evangelos Terpos,Irit Avivi,Meletios A. Dimopoulos +10 more
Journal ArticleDOI
The Serum Levels of N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) Is a Strong Indicator of Pulmonary Hypertension in Patients with Sickle Cell/Beta Thalassemia.
TL;DR: The aim of this study was to evaluate the prevalence of PH in correlation with hemolytic findings and NT-proBNP levels in 73 patients with HbS/beta-thalassemia and found that patients with PH had elevated values ofNT-pro BNP, reticulocyte counts and serum ferritin and a borderline increase of HbF compared with non PH patients.
Journal ArticleDOI
Indirubins: A Potential Therapeutic Target in Multiple Myeloma
Tina Bagratuni,Nicolas Gaboriad-Kolar,Roubini Zakopoulou,Vassilios Myrianthopoulos,Efstathios Kastritis,Evangelos Terpos,Emmanuel Mikros,Alexios-Leandros Skaltsounis,Meletios A. Dimopoulos +8 more
TL;DR: In this paper, the structure-based virtual screening and ligand-based approach were used to evaluate the effect of 6-bromoindirubin derivatives on multiple myeloma (MM) cell lines.
Journal Article
Hodgkin's lymphoma
Amin Rahemtulla,Evangelos Terpos +1 more
TL;DR: A systematic review of the effectiveness and safety of the following interventions to answer clinical questions about the effects of single-regimen chemotherapy treatments, combined chemotherapy and radiotherapy treatments compared with radiotherapy alone, and increased-dose regimens.
Journal ArticleDOI
P22: a non-interventional, prospective, observational study of relapsed/refractory multiple myeloma patients treated with ixazomib in real-world settings in greece; interim results of the ‘ol-oral’ study
Eirini Katodritou,M.-C. Kyrtsonis,Sosana Delimpasi,Emmanouil Spanoudakis,George Vassilopoulos,Panagiotis Zikos,Nora Viniou,Georgia Kaiafa,Michalis V. Papathanasiou,V. B. Rathi Pappa,Eurydiki Michalis,Ioannis Adamopoulos,Kiriaki Kokoviadou,George Tsirakis,Christos Poziopoulos,Evangelos Terpos +15 more
TL;DR: The PFS2 in this subgroup supports that disease control can be achieved by sequencing of sAMT after relapse from anti-BCMA CAR T therapy, and studies are ongoing to define tumor phenotypes prior to and after ide-cel that may correlate with these clinical observations.